scholarly journals Dual Therapy With Darunavir and Ritonavir Plus Lamivudine vs Triple Therapy With Darunavir and Ritonavir Plus Tenofovir Disoproxil Fumarate and Emtricitabine or Abacavir and Lamivudine for Maintenance of Human Immunodeficiency Virus Type 1 Viral Suppression: Randomized, Open-Label, Noninferiority DUAL-GESIDA 8014-RIS-EST45 Trial

2017 ◽  
Vol 65 (12) ◽  
pp. 2112-2118 ◽  
Author(s):  
Federico Pulido ◽  
Esteban Ribera ◽  
María Lagarde ◽  
Ignacio Pérez-Valero ◽  
Rosario Palacios ◽  
...  
Keyword(s):  
Human Immunodeficiency Virus ◽  
Triple Therapy ◽  
Human Immunodeficiency Virus Type ◽  
Virus Type ◽  
Tenofovir Disoproxil Fumarate ◽  
Viral Suppression ◽  
Dual Therapy ◽  
Open Label ◽  
Immunodeficiency Virus

Emergence of Dual Resistance to Zidovudine and Lamivudine in Clinical HIV-1 Isolates from Patients Receiving Zidovudine/Lamivudine Combination Therapy

1998 ◽  
Vol 3 (2) ◽  
pp. 97-102
Author(s):  
Rebekah JA Gass ◽  
Dave Shugarts ◽  
Russell Young ◽  
Michael Allen ◽  
Mary Rosandich ◽  
...  
Keyword(s):  
Human Immunodeficiency Virus ◽  
Combination Therapy ◽  
Human Immunodeficiency Virus Type ◽  
Virus Type ◽  
Single Agent ◽  
Dual Therapy ◽  
Zidovudine Treatment ◽  
Immunodeficiency Virus ◽  
Hiv 1

Susceptibility to zidovudine and lamivudine was determined on human immunodeficiency virus type 1 (HIV-1) isolates obtained from patients who added lamivudine after 6 months of treatment with zidovudine. Lamivudine-resistant isolates that were also zidovudine-resistant were recovered from 13/16 (81%) patients after 6 months of dual therapy. In contrast to findings in anti-retroviral therapy-naive patients, these results suggest that dual resistance to zidovudine and lamivudine emerges relatively quickly when lamivudine is added to zidovudine as a single agent in the majority of patients with extensive prior zidovudine treatment.

scholarly journals Adjunctive Passive Immunotherapy in Human Immunodeficiency Virus Type 1-Infected Individuals Treated with Antiviral Therapy during Acute and Early Infection

2007 ◽  
Vol 81 (20) ◽  
pp. 11016-11031 ◽  
Author(s):  
Saurabh Mehandru ◽  
Brigitta Vcelar ◽  
Terri Wrin ◽  
Gabriela Stiegler ◽  
Beda Joos ◽  
...  
Keyword(s):  
Human Immunodeficiency Virus ◽  
Human Immunodeficiency Virus Type ◽  
Virus Type ◽  
Early Infection ◽  
Treatment Modalities ◽  
Viral Rebound ◽  
Open Label ◽  
Immunodeficiency Virus

ABSTRACT Three neutralizing monoclonal antibodies (MAbs), 2G12, 2F5, and 4E10, with activity in vitro and in vivo were administered in an open-label, nonrandomized, proof-of-concept study to attempt to prevent viral rebound after interruption of antiretroviral therapy (ART). Ten human immunodeficiency virus type 1-infected individuals identified and treated with ART during acute and early infection were enrolled. The first six patients were administered 1.0 g of each of the three MAbs per infusion. The remaining four patients received 2G12 at 1.0 g/infusion and 2.0 g/infusion of 2F5 and 4E10. The MAbs were well tolerated. Grade I post-partial thromboplastin time prolongations were noted. Viral rebound was observed in 8/10 subjects (28 to 73 days post-ART interruption), and 2/10 subjects remained aviremic over the course of the study. In seven of eight subjects with viral rebound, clear resistance to 2G12 emerged, whereas reductions in the susceptibilities of plasma-derived recombinant viruses to 2F5 and 4E10 were neither sustained nor consistently measured. Viral rebound was associated with a preferential depletion of CD4+ T cells within the gastrointestinal tract. Though safe, the use of MAbs generally delayed, but did not prevent, virologic rebound. Consideration should be given to further pilot studies with alternative combinations of MAbs and perhaps additional novel treatment modalities.

Sign in / Sign up

Export Citation Format

Share Document